Cumberland Pharmaceuticals refined the terms of its asset divestiture by signing Amendment No. 1 to the Asset Purchase Agreement with Nuvo on July 1, 2026, excluding certain contracts from the assets transferred. In connection with the closing, the company also terminated its Revolving Credit Loan Agreement with Pinnacle Bank on June 29, 2026, repaying approximately $5.3 million and releasing all related liens. Together, these steps align the $100 million transaction’s scope and simplify the balance sheet post-closing.
New agreement details:
- Agreement type: Amendment No. 1 to Asset Purchase Agreement
- Counterparty: Nuvo Pharmaceuticals (Ireland)
- Signed / Effective: Jul 01 2026 / Jul 01 2026
- Duration / Termination: At will
- Reason: Refine asset scope before closing
Terminated agreement details:
- Agreement terminated: Revolving Credit Loan Agreement
- Counterparty: Pinnacle Bank
- Original agreement date: Sep 05 2023
- Termination date: Jun 29 2026
- Termination type: Early
- Exit fees / payments: None
- Reason: Repay debt upon asset sale closing
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.